Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600-mutant melanoma.
Helen Gogas(National and Kapodistrian University of Athens), Reinhard Dummer(University Hospital of Zurich), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Keith T. Flaherty(Cancer Research Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Ashwin Gollerkeri(Peter MacCallum Cancer Centre), Michael D. Pickard(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jan Willem de Groot(Isala), Carmen Loquai(Johannes Gutenberg University Mainz), Claus Garbe(University of Tübingen), Caroline Robert(Institut Gustave Roussy), Ivana Krajsová(Charles University)
Cited by 23
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k